U.S. Businesses using ClinicalTrials.gov to market unproven and unlicensed stem cell interventions

Written by Regenerative Medicine

To further public understanding of regenerative medicine, EuroStemCell has published lay summaries for all articles from the latest Regenerative Medicine special focus issue. EuroStemCell have launched a digital platform to accompany the publication of the Regenerative Medicine two-part Special Focus Issue entitled “Regenerative Medicine in Society: Interdisciplinary Perspectives”. The platform presents lay summaries of each article in the issue which are freely available to all in order to engage and educate non-experts on the key issues surrounding regenerative medicine. You can now read the lay summary for the article entitled, “ClinicalTrials.gov, stem cells and ‘pay-to-participate’ clinical studies” from Leigh Turner [1]. Businesses...

To view this content, please register now for access

It's completely free